Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI
Recruiting
Phase 3
Interventional Study
Neurocognitive Dysfunction
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 5 – 39
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 101 (estimated)
- Sponsor
- Tata Memorial Centre · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine lea…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age at irradiation: 5 to 39 years
* Planned for CSI (with or without boost dose) with or without systemic chemotherapy
* Informed consent or assent taken
* Karnofsky Performance Status / Lansky Performance Status ≥ 60
Exclusion Criteria:
* Re-irradiation
* Prior exposure to …
Contacts